Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (HKSE: 9989) is trading at HK$4.06, about ₹50 at today's HKD/INR rate, as of 30 Sep 2026, 4:08 AM ET, up 2.79% today. Indian residents can buy Shenzhen Hepalink Pharmaceutical Group from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$3.93
Today's high
HK$4.06
52 week low
HK$3.74
52 week high
HK$5.77
9989 opened at HK$3.95, closed previously at HK$3.95, and has traded between HK$3.74 and HK$5.77 over the past 52 weeks.
About
Shenzhen Hepalink Pharmaceutical Group Co., Ltd., founded in 1998 and headquartered in Shenzhen, People's Republic of China, operates as an international pharmaceutical company. It is involved in the development, production, and distribution of a wide array of pharmaceutical goods, serving markets in Hong Kong, the United States, Europe, Mainland China, and other global regions. The company's operations are structured across four primary divisions. One key area is Finished Dose Pharmaceutical Products, prominently featuring enoxaparin sodium injection. Another significant segment focuses on Active Pharmaceutical Ingredients (API), supplying essential components like heparin sodium API, enoxaparin sodium API, and other specialized products such as pancreatin API. Hepalink also provides comprehensive services through its Contract Development and Manufacturing Organization (CDMO) arm, which encompasses research and development, manufacturing, quality assurance, and program management. Within its CDMO capabilities, the company is actively involved in creating advanced biopharmaceutical products, including recombinant pharmaceuticals, critical non-viral vectors, gene therapy intermediates, and naturally derived pharmaceutical substances. Beyond its core pharmaceutical activities, Hepalink diversifies its business interests through property management, investment management and advisory services, biopharmaceutical technology development and consulting, and equity and venture capital investments. The company also conducts research, development, and production of biopharmaceuticals, trades medical and biopharmaceutical products, and offers various pharmaceutical-related services. The company officially changed its name from Shenzhen Hepalink Pharmaceutical Co., Ltd. to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017.
Key statistics
Avg. volume
569.68K
Market cap
HK$13.69B
P/E Ratio
70.56
Price-to-sales ratio
2.34
Enterprise value
CN¥7.63B
Free cash flow yield
23.18%
Debt-to-equity ratio
0.25
Return on equity
2.90%
ROIC
3.75%
Beta
0.31
Dividend yield
1.47%
Last dividend
HK$0.17
Financial overview
Revenue
CN¥5.48B
Earnings per share
CN¥0.24
Free cash flow
CN¥1.59B
Net profit margin
3.87%
Gross margin
33.81%
EBITDA
CN¥846.59M
Revenue growth
3.75%
Similar securities
This is not an investment recommendation
How to buy Shenzhen Hepalink Pharmaceutical Group from India
Indian residents can buy Shenzhen Hepalink Pharmaceutical Group shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Shenzhen Hepalink Pharmaceutical Group and place an order
Find Shenzhen Hepalink Pharmaceutical Group by name or by its ticker, 9989, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Shenzhen Hepalink Pharmaceutical Group trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Shenzhen Hepalink Pharmaceutical Group position in HKD and INR, and use Paasa's capital-gains and dividend statements when you file your Indian return.
Read the full guide: how to invest in Shenzhen Hepalink Pharmaceutical Group from India
Trading and taxes when buying Shenzhen Hepalink Pharmaceutical Group from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- Slab rateDividends are taxed at your slab rate in India. Shenzhen Hepalink Pharmaceutical Group’s current yield is 1.47%.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Shenzhen Hepalink Pharmaceutical Group stock?
Yes. Shenzhen Hepalink Pharmaceutical Group (9989) has been listed on the Hong Kong Stock Exchange since 2020, in the Drug Manufacturers - Specialty & Generic industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Shenzhen Hepalink Pharmaceutical Group share cost in rupees?
One Shenzhen Hepalink Pharmaceutical Group share is HK$4.06 — about ₹50 at an HKD/INR rate of 12.24 on 29 Sep 2026. Both the Shenzhen Hepalink Pharmaceutical Group price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Shenzhen Hepalink Pharmaceutical Group from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Shenzhen Hepalink Pharmaceutical Group?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Shenzhen Hepalink Pharmaceutical Group shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Shenzhen Hepalink Pharmaceutical Group price. Paasa issues a capital-gains statement for your return.
Does Shenzhen Hepalink Pharmaceutical Group pay a dividend, and how is it taxed in India?
Yes. Shenzhen Hepalink Pharmaceutical Group pays a dividend and the current yield is 1.47%; the last declared dividend was HK$0.17 per share, about ₹2.03. Dividends are taxed at your slab rate in India. Paasa's dividend report lists the gross dividend and any tax withheld for each payment.
When can I trade Shenzhen Hepalink Pharmaceutical Group from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Shenzhen Hepalink Pharmaceutical Group a Hong Kong SAR China company, and does that change how it is taxed?
Shenzhen Hepalink Pharmaceutical Group trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Shenzhen Hepalink Pharmaceutical Group trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Shenzhen Hepalink Pharmaceutical Group shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Shenzhen Hepalink Pharmaceutical Group holding, its cost and its closing value.
How do I sell Shenzhen Hepalink Pharmaceutical Group and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.